Table 4

Changes in generic and disease-specific quality of life and symptom severity during 6–24 months of follow-up*

Additional catheter-directed thrombolysis (n=90)Standard treatment only (n=99)
n% (95% CI)n% (95% CI)p Value†
Generic QOL
 EQ-5D improved1516.7 (10.0 to 24.4)2424.5 (16.6 to 33.4)0.233
 EQ-5D worsened2224.4 (16.4 to 34.1)1616.3 (9.9 to 24.4)
Disease-specific QOL
 VEINES-QOL improved1719.5 (11.8 to 28.0)2727.3 (19.2 to 36.7)0.462
 VEINES-QOL worsened1921.8 (13.6–30.4)1919.2 (12.3 to 27.8)
 VEINES-Sym improved1415.9 (9.1 to 24.2)3232.3 (23.7 to 42.0)0.029
 VEINES-Sym worsened2022.7 (14.5 to 31.7)2121.2 (14.0 to 30.1)
PTS (n=92)No PTS (n=97)
Generic QOL
 EQ-5D improved1516.5 (9.8 to 24.9)2424.7 (16.9 to 34.0)0.041
 EQ-5D worsened2527.5 (18.8 to 36.9)1313.4 (7.7 to 21.3)
Disease-specific QOL
 VEINES-QOL improved2123.3 (15.1 to 32.2)2324.0 (16.1 to 32.9)0.017
 VEINES-QOL worsened2628.9 (19.8 to 38.1)1212.5 (6.9 to 20.1)
 VEINES-Sym improved2022.0 (14.2 to 31.0)2627.1 (18.7 to 36.3)0.017
 VEINES-Sym worsened2830.8 (21.7 to 40.4)1213.5 (7.7 to 21.3)
  • *A meaningful change was defined as ≥4 points for VEINES-QOL/Sym scores and ≥0.08 for the EQ-5D index; improvement or worsening below this was registered as no change.

  • †χ2 test.

  • QOL, quality of life.